It will be interesting to see the final phase 1 results . With the NSCLC the industry leader appears to be DNAs Avastin in combo with paclitaxel/carboplatin.
>>Progression-free and overall survival were also significantly improved; the average progression-free survival was 6.4 months in the Avastin treatment group, compared to 4.5 months in the chemotherapy alone group. The average overall survival was 12.5 months in the Avastin group, compared to 10.2 months for the patients who received paclitaxel/carboplatin.<<
After 50 years R&D into NSCLC sadly 6.4 months TTP and 12.5 months survival is not much to beat .
- Forums
- ASX - By Stock
- trials continue...
SBP
solbec pharmaceuticals limited
It will be interesting to see the final phase 1 results . With...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online